Company overview. Louisiana Health Service & Indemnity Company, doing business as Blue Cross and Blue Shield of Louisiana (rebranded "Louisiana Blue" in 2024), is a nonprofit, policyholder-owned mutual health insurer headquartered at 5525 Reitz Avenue, Baton Rouge, Louisiana. It was founded in New Orleans in 1934 as the Hospital Service Association of New Orleans and is an independent licensee of the Blue Cross Blue Shield Association. It has no public ticker and no parent company. The company reports 3,000+ employees and roughly 1.9 million members; third-party estimates put revenue near $3.7 billion (Owler), while Elevance Health cited ~$4.5 billion in revenue for the plan it sought to buy. In January 2023 BCBSLA agreed to a ~$2.5 billion acquisition by Elevance Health; the plan was withdrawn in February 2024 after opposition from providers, policyholders, and state officials, and the deal lapsed when its exit clause expired in April 2024 (company press release; Louisiana Department of Insurance; Becker's).
Products / operations. BCBSLA is an operating insurance company, not an NPE. It sells fully insured and self-insured (administrative-services-only) group health plans, individual and family coverage, Medicare Advantage and Medicare supplement plans, prescription drug coverage, and voluntary dental, life, and disability benefits. Subsidiaries include HMO Louisiana, Inc. (a wholly owned HMO and co-plaintiff in the case below) and Southern National Life Insurance Company.
Patent-litigation posture. The database shows one tracked case, with BCBSLA as plaintiff and zero as defendant — consistent with an operating company that litigates as a purchaser, not an entity asserting patents. The suit is an antitrust action, not a patent-infringement claim, and is in the Southern District of New York, not a plaintiff-friendly patent venue such as the Eastern District of Texas.
Notable case. Louisiana Health Service & Indemnity Co. (BCBS LA) et al. v. Celgene Corp. et al., No. 1:23-cv-07871 (S.D.N.Y., filed Sept. 5, 2023), was an end-payor class action against Celgene, Bristol Myers Squibb, and individuals Anthony Insogna and Jerome Zeldis, alleging fraudulent patent procurement, sham Hatch-Waxman litigation, and reverse-payment settlements delayed generic pomalidomide (Pomalyst). The court dismissed the first amended complaint for failure to state a claim on March 31, 2025, and the docket reflects a subsequent dismissal and denial of leave to amend in April 2026 (CourtListener; Reuters/FiercePharma).